GSM5359436
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.500
- INFLAMMATORY_RESPONSE+0.420
- ALLOGRAFT_REJECTION+0.410
- KRAS_SIGNALING_DN+0.410
- KRAS_SIGNALING_UP+0.350
- HEDGEHOG_SIGNALING+0.340
- IL6_JAK_STAT3_SIGNALING+0.310
- TNFA_SIGNALING_VIA_NFKB+0.310
- APICAL_SURFACE+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
Top 10 suppressed
- MYC_TARGETS_V1-0.560
- OXIDATIVE_PHOSPHORYLATION-0.530
- PROTEIN_SECRETION-0.510
- DNA_REPAIR-0.430
- TGF_BETA_SIGNALING-0.400
- MYC_TARGETS_V2-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.370
- MTORC1_SIGNALING-0.360
- ADIPOGENESIS-0.350
- NOTCH_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1331289 | GTEX | — | 0.934 |
| 2 | SRR13311178 | — | — | 0.930 |
| 3 | MNG1146 | — | — | 0.927 |
| 4 | SRR659472 | GTEX | — | 0.918 |
| 5 | SRR8943034 | — | — | 0.918 |
| 6 | MNG272 | — | — | 0.916 |
| 7 | SRR602839 | GTEX | — | 0.914 |
| 8 | SRR1375616 | GTEX | — | 0.913 |
| 9 | SRR1429957 | GTEX | — | 0.913 |
| 10 | SRR1418604 | GTEX | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.500 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.410 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |